Clinical Trial in Males With BPH (Enlarged Prostate)
Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.
Sponsor: Sanofi
Listed as NCT00029822, this PHASE3 trial focuses on Benign Prostatic Hypertrophy and Prostatic Hyperplasia and remains completed. Sponsored by Sanofi, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Athens, Greece, Aurora, United States, Aventura, United States, Baltimore, United States, Barcelona, Spain, Bromma, Sweden, Bucharest, Romania, Budapest, Hungary, Chicago, United States, Clearwater, United States and 44 more location s